Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 4/20 | 0.53 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 6/20 | 0.47 |
| ▸ | CNR2 | P34972 | 6/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9979716 | 0.87 | CNR1 (0.61) | CA9CHRNA7ALDH1A1CNR1CNR2 | |
| SCHEMBL28820555 | 0.84 | CNR1 (0.61) | CA9CHRNA7ALDH1A1CNR1CNR2 | |
| SCHEMBL31377474 | 0.84 | ALDH1A1 (0.68) | CA9ALDH1A1CNR1CNR2GAA | |
| SCHEMBL1107620 | 0.83 | ALDH1A1 (0.70) | PTGS2ALDH1A1CNR1CNR2EPHX2 | |
| SCHEMBL12594103 | 0.83 | ALDH1A1 (0.55) | CHRNA7PTGS2ALDH1A1CNR1CNR2 | |
| SCHEMBL1107588 | 0.80 | GRN (0.49) | CA9CHRNA7PTGS2ALDH1A1CA12 | |
| SCHEMBL9204895 | 0.80 | CA9 (0.82) | CA9CHRNA7PTGS2 | |
| SCHEMBL9941326 | 0.80 | CA9 (0.82) | CA9CHRNA7PTGS2EPHX2 | |
| SCHEMBL6511261 | 0.78 | CA9 (0.69) | CA9CHRNA7PTGS2 | |
| SCHEMBL7627415 | 0.78 | CHRNA7 (0.83) | CA9CHRNA7PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096532-B2 | Pyrazole inhibitors of COX-2 and sEH | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096532-B2 | Pyrazole inhibitors of COX-2 and sEH | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096532-B2 | Pyrazole inhibitors of COX-2 and sEH | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140038923-A1 | PYRAZOLE INHIBITORS OF COX-2 AND SEH | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-02-06 | — | — | US | disclosed |
| US-20140038923-A1 | PYRAZOLE INHIBITORS OF COX-2 AND SEH | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-02-06 | — | — | US | disclosed |
| US-20140038923-A1 | PYRAZOLE INHIBITORS OF COX-2 AND SEH | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-02-06 | — | — | US | disclosed |
| WO-2012082647-A2 | PYRAZOLE INHIBITORS OF COX-2 AND sEH | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012082647-A2 | PYRAZOLE INHIBITORS OF COX-2 AND sEH | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-06-21 | — | — | WO | disclosed |
| US-20120142636-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2012-06-07 | — | — | US | disclosed |
| US-20120142636-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2012-06-07 | — | — | US | disclosed |
| US-8153677-B2 | Substituted pyrazolylamide compounds useful as glucokinase activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-10 | — | — | US | disclosed |
| US-7910747-B2 | Phosphonate and phosphinate pyrazolylamide glucokinase activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-22 | — | — | US | disclosed |
| US-20080009465-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-10 | — | — | US | disclosed |
| WO-2008005964-A2 | PHOSPHONATE AND PHOSPHINATE COMPOUNDS AS GLUCOKINASE ACTIVATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009465-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, GCK, PCK1 | CA9 549/4885CHRNA7 931/4885PTGS2 3837/4885 |
| US-20140038923-A1 | PYRAZOLE INHIBITORS OF COX-2 AND SEH | PTGES2, PTGS2, PTGES3 | CA9 4178/4885CHRNA7 4608/4885PTGS2 2/4885 |
| US-20120142636-A1 | NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCKR, GCK, PCK1 | CA9 412/4885CHRNA7 984/4885PTGS2 3999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.